Faricimab therapy for neovascular age-related macular degeneration and diabetic macular edema has a low incidence of intraocular inflammation adverse events, which are generally mild and have a favorable prognosis, according to a study.
The study analyzed electronic medical records for 2,318 eyes from 1,860 patients who received 10,297 faricimab injections. Intraocular inflammation events, excluding endophthalmitis, were reported in 20 eyes (16 patients), for an incidence of 0.19% per injection and 0.86% per patient. Most cases occurred early in the treatment course, with a median of 3.5 injections.
All intraocular inflammation cases presented as anterior uveitis, with vitritis observed in 20% of affected eyes. No cases of posterior uveitis or retinal vascular occlusion were reported. Visual acuity remained stable before and after the intraocular inflammation events, with no significant difference noted.
The study concluded that faricimab was well tolerated in real-world settings, with an incidence of IOI-related AEs consistent with clinical trial data.
Reference
Montesel A, Sen S, Preston E, et al. Intraocular Inflammation (IOI) Associated with Faricimab Therapy: One-year Real World Outcomes. Retina. 2025;doi: 10.1097/IAE.0000000000004394. Epub ahead of print. PMID: 39761510.
Related Content
